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Abstract 
Background:  The World Health Organization’s regulations, dating back to 1951, emphasize 
the role of expert opinion in the development of recommendations. Guidelines for WHO 
guidelines, approved in 2003, instead emphasize systematic reviews of evidence of effects, 
processes that allow for the explicit incorporation of other types of information (including 
values), and evidence-informed dissemination and implementation strategies. We examined 
the use of evidence, particularly evidence of effects, in recommendations developed by WHO 
departments. 
 
Methods:  We conducted interviews with department directors (or their delegates) at WHO 
headquarters and reviewed a sample of the recommendation-containing reports that were 
discussed in the interviews (as well as related background documentation). Two individuals 
independently conducted a thematic analysis of the interviews and reviewed key features of 
the recommendation-containing reports (and related background documentation). 
 
Findings:  Systematic reviews and concise summaries of findings are rarely used. Processes 
for developing recommendations typically rely heavily on experts in a particular content area 
and not on representatives of those who will have to live with the recommendations or on 
experts in particular methodological areas. Relatively little attention has been given to how to 
best help member states adapt global recommendations or take account of local needs, 
conditions, resources, costs, and values. Relatively little attention has also been given to roles 
and responsibilities related to effective dissemination and implementation strategies and their 
rigorous evaluation. 
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Interpretation:  Progress in the development, adaptation, dissemination and implementation of 
recommendations for member states will require leadership, the resources necessary for WHO 
to undertake these processes in a transparent and defensible way, and close attention to the 
current and emerging research literature related to these processes. 
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The use of evidence in WHO recommendations 
Each year the World Health Organization (WHO) develops a large number of 
recommendations aimed at many different target audiences, including the general public, 
healthcare professionals, managers working in health facilities (e.g., hospitals) or regions 
(e.g., districts), and public policymakers in member states. These recommendations address a 
wide range of clinical, public health and health policy topics related to achieving health goals. 
WHO’s regulations, dating back to 1951, emphasize the role of expert opinion in the 
development of recommendations. In the fifty-five years since these regulations were 
developed, research has highlighted the limitations of expert opinion. For example, expert 
opinion can differ both across sub-groups and from the opinions of those who will have to 
live with the consequences of expert recommendations,1-8 and experts have been found to use 
non-systematic methods when they review research, which frequently result in 
recommendations that do not reflect systematic summaries of the best available evidence.9,10  
 
Evidence of the effects of alternative policies, programs and services is essential for well-
informed decisions. Systematic reviews have several advantages over other approaches to 
amassing evidence of effects.11-13 Firstly, systematic reviews reduce the risk of bias in 
selecting studies and interpreting their results. Secondly, they reduce the risk of being misled 
by the play of chance in identifying studies for inclusion, or the risk of focusing on a limited 
subset of relevant evidence. Thirdly, systematic reviews provide a critical appraisal of the 
available evidence and place individual studies or subgroups of studies in the context of all of 
the relevant evidence. Finally, they allow others to appraise critically the judgements made in 
selecting studies and the collection, analysis and interpretation of the results. However, 
systematic reviews can only be as good as the evidence that they summarize. There may be no 
evidence. When there is evidence, judgements are still required about the quality of the 
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evidence and, particularly for public health and health policy topics, its applicability in 
different contexts.12 
 
Evidence of effects needs to be complemented by information about needs, factors that 
may affect whether effectiveness will be realized in the field, available resources, costs, and 
the values of those who will be affected by the recommendations. Processes that allow for the 
explicit incorporation of these other types of information, particularly values, have (like 
systematic reviews) emerged as central to the development of recommendations.14-18 Moving 
from evidence to recommendations requires judgements, particularly judgements about goals 
and about the balance between the desirable and undesirable consequences of choosing one 
option over another to achieve these goals.  
 
Evidence-informed dissemination and implementation strategies are increasingly 
recognized as a core part of the business of developing recommendations. Those charged with 
developing clinical practice guidelines can draw on a systematic review of randomized 
controlled trials of guideline dissemination and implementation strategies to inform their 
efforts. 19,20 While there are no magic bullets and few strategies have been evaluated in low 
and middle-income countries, such efforts clearly can have an effect.21 Those charged with 
developing recommendations targeted at managers or public policymakers, on the other hand, 
have to deduce the attributes of the interventions from systematic reviews of observational 
studies and begin to build an evidence base about the effectiveness of these interventions. 13,,22 
 
WHO has recognised the need to revise its approach to developing recommendations, as 
reflected in the guidelines for WHO guidelines, which were approved by the WHO Cabinet in 
2003.23 We sought to examine the use of evidence in WHO recommendations subsequent to 
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this. We particularly wanted to explore the use of evidence of effects. Our hope was that such 
stock-taking would inform debates about how WHO could improve how it develops and 
disseminates recommendations and how WHO could better support member states in their 
efforts to adapt and implement recommendations. 
 
Methods 
We conducted interviews with department directors (or their delegates) at WHO 
headquarters and reviewed a sample of the recommendation-containing reports that were 
discussed in the interviews. We invited the participation of all department directors in five 
departmental clusters that had a content focus: non-communicable diseases and mental health 
(six departments); HIV/AIDS, TB and malaria (four); family and community health (four); 
communicable diseases (three); and health technology and pharmaceuticals (two). We invited 
the participation of one department (of five) in the sustainable development and healthy 
environments cluster and three departments (of five) in the evidence and information for 
policy cluster. We did not invite the participation of the department directors in the two 
clusters -- the external relations and governing bodies cluster and the general management 
cluster -- that had a corporate focus. While our e-mailed request for an interview was 
introduced by a WHO department director, we made clear that we were conducting the study 
independently of WHO and that we planned to publish the results after first making them 
available to WHO. We purposively sampled four of the reports identified by the interviewees 
on the basis of their focus on clinical treatment, centrality to major WHO initiatives, and 
relevance to the Millennium Development Goals. The first criterion was chosen to maximize 
the chances that evidence of effects would be available and that the reports could be expected 
to meet current standards for clinical practice guidelines. 
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Two individuals participated in each interview. One individual had primary responsibility 
for conducting the interview and the other for audio taping the interview and taking notes. 
The brief structured part of each interview focused on the number and background of staff 
members and the number and type of recommendation-containing reports published in the last 
year. The semi-structured part of each interview focused primarily on the development of 
recommendations contained in one or two specific published guidelines or policies that were 
selected by interviewees from among those their department had developed or had a major 
responsibility in developing. For each guideline or policy we asked about: why it was 
developed; the process used (including whether support was received from others within or 
outside WHO, whether evidence of effects and other types of information were used, whether 
and how supporting documentation was made publicly available, and whether and how plans 
for updating were established); strengths of the processes used and elements that could have 
been improved upon; likely benefits, harms and costs of adhering to the recommendations; 
how the recommendations have been used and any plans for evaluating the effects of 
adherence to the recommendations; and the availability of any background documentation.  
 
Two individuals independently conducted a thematic analysis of the interviews and 
reviewed key features of the recommendation-containing reports (and related background 
documentation). We began the thematic analysis by using the notes taken during each 
interview (supplemented by the corresponding audiotape) to produce a summary of each 
interview, including the major themes that emerged. We then sent the summary to each 
interviewee with a request that they verify our interpretations and, if they wished, provide 
additional comments and/or reflections. We used the audiotapes to identify illustrative 
quotations for each major theme. We began the document review by recording for each 
document its type, whether it included a section that described the methods that were used, 
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the number of recommendations that were based on a systematic review, the number of 
systematic reviews cited, and the description that was provided of the development process 
that was used. We then produced a summary for each recommendation-containing report. We 
presented our findings at a variety of forums within WHO as an additional check on our 
interpretations.  
 
The study was sponsored as part of a broader project -- Pragmatic randomized controlled 
trials in health care (www.practihc.org) -- funded by the European Commission's 5th 
Framework International Collaboration with Developing Countries, Research.  WHO was a 
formal partner in Practihc, however, as a partner WHO staff input was limited to commenting 
on the protocol and interview questions. Additional input from WHO staff was limited to 
providing comments on the interview summaries (for those who were interviewed) and 
overall findings (for those who attended forums where these were presented). The sponsors of 
the study had no role in the design (beyond commenting on the protocol and interview 
questions), data collection, data analysis, data interpretation (beyond commenting on the 
interview summaries and overall findings), writing or revising of the report. ADO, as 
corresponding author, had full access to all data in the study and had final responsibility to 
submit a report for publication. 
 
Results  
We conducted 23 interviews with 29 people and we reviewed four recommendation-
containing reports and related background documentation. We interviewed the director in 15 
departments and someone designated by the director in six departments. Three of the 
interviews were with more than one person. For two departments we conducted two separate 
interviews with different people from the department. We were unable to arrange interviews 
with the directors (or delegates) of two departments that had newly appointed directors who 
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were not yet in post. The interviews, which lasted one hour or less, were conducted between 
September 2003 and February 2004. Five of the 21 participating departments did not produce 
formal recommendations so their interviews were not included in the analysis, which is 
therefore based on 17 interviews with 21 people (across 16 departments). The four 
recommendation-containing reports that we selected for review were clinical practice 
guidelines that addressed antiretroviral therapy for HIV, treatment of tuberculosis, treatment 
of malaria, and Integrated Management of Childhood Illness (IMCI).24-27 
 
Who is producing what types of recommendations and why? 
The directors or their delegates (hereafter directors) of the 16 departments that developed 
recommendations reported that their departments had between eight and 170 staff members 
each (median 55) and close to 1000 staff members in total. The directors estimated that 
between 20% and 80% of staff members had some background in research (median 30%). 
Many directors found it difficult to quantify the number of recommendation-containing 
reports that their department published each year given the variety of formats in which 
recommendations could appear. Their estimates ranged from one to 45 reports per department 
per year (median 8) and totalled close to 180 reports per year. 
 
The reports varied widely in the nature of the topics they addressed. In addition to clinical 
treatment topics, the reports addressed topics like malaria control using impregnated bed nets, 
promotion of mental health, helminthic guidelines for managers, human resources policy 
development, model list of essential medicines, tobacco legislation, and bioterrorism. The 
directors cited a number of reasons for developing recommendations, the most common of 
which were a perceived need for guidance, a perceived need for updating existing 
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recommendations, and demand from member states. One report was developed to respond to 
criticisms of previous recommendations. 
 
How are recommendations being developed? 
Expert committees or meetings of experts were almost always convened when developing 
recommendations whereas only a few directors mentioned having commissioned systematic 
reviews to inform the work of these expert groups. Some directors reported the use of a 
combination of work done “in house” and an expert committee or the combination of a small 
“task force” to draft recommendations and either an expert committee or a review by external 
experts. A fair number of directors reported a phase of external consultation or review. Only a 
few directors mentioned developing dissemination or implementation strategies. Most 
directors reported the involvement of one or more other WHO departments in the 
development process and nearly all reported some form of external support. No directors 
mentioned drawing on any form of internal support in the methodological or technical aspects 
of developing recommendations. The external support typically took the form of expert 
committee members, but sometimes involved expert advisors, writers of background reports 
and recommendation-containing reports, and reviewers. 
 
When asked specifically about using evidence of effects, only a small number of directors 
reported using systematic reviews of such evidence and none reported using concise 
summaries of findings (e.g., balance sheets) for the most important outcomes (benefits, harms 
and costs) of each option being considered. Many directors instead reported using background 
documents, although there was little consistency in how the documents were prepared. For 
example, some background documents were prepared by the participating experts according 
to their own conventions. Other directors reported leaving the use of evidence up to the 
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experts, feeling that evidence of effects was not relevant for some recommendations, and 
feeling that randomized trials were not appropriate for some types of interventions. Only one 
director reported grading the quality of the evidence. 
 
When asked about using other types of information, a number of directors reporting using 
data about costs but only a couple mentioned using data about potential harms or explicitly 
considering values; i.e. the relative importance or worth of the consequences (benefits, harms 
and costs) of a decision.18 Using data about potential harms was only mentioned in relation to 
clinical interventions, particularly pharmaceuticals, and not for public health or policy 
interventions. Explicitly considering values was undertaken in a very general way. One 
director talked about the “weighing of values, which basically reflected the composition of the 
panel.” Another director commented: 
 
“Values were also brought into debate. For example, experience for high income countries 
suggest that encouraging more self efficacy and independency for young people could be 
effective in preventing mental health problems and substance use. However, this was by 
many considered as to be contrary to important values for people living in many low-
income countries.” 
 
While directors were not asked specifically about group processes, many volunteered 
descriptions that suggested that these processes were not particularly structured with respect 
to group composition, format or rules. The directors’ descriptions suggested that participants 
were implicitly weighing evidence of effects, harms, and costs along with values and many 
other types of information (e.g., surveys, resistance patterns, other epidemiological data, 
availability of interventions, country experiences, political considerations, cultural 
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differences, ethical considerations, and “undocumented knowledge”). One director clearly 
recognized the challenges associated with a lack of structured process: 
 
 “There is a tendency to get people around the table and get consensus (everything they do 
has a scientific part and a political part). This usually means you go to the lowest common 
denominator or the views of a “strong” person at the table.” 
 
Most directors reported that the information that was used by the committees was not 
published but that it was often made publicly available in some form. The format for the 
documentation varied widely, including a bibliography in the report, one or more published 
articles (e.g., a special edition of the WHO Bulletin), one or more reports (e.g., annual reports, 
multi-country evaluation reports, and proceedings of meetings), a book, and an adaptation 
guide. The documentation was sometimes readily available (e.g., on a website) and other 
times required personal contact with those involved in developing the recommendations. 
While one director reported updating recommendations every two years and some other 
directors reported that their recommendations were considered one-off initiatives that would 
not be updated, most directors reported ad hoc approaches to deciding whether and when to 
update recommendations. One director reported plans to update the recommendations using 
the guidelines for WHO guidelines. 
 
What is being done well and what could be improved? 
The directors identified a number of strengths in the processes used for developing 
recommendations and in the recommendations themselves. The most commonly identified 
strength was bringing together or consulting with a wide range of people. Most other 
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strengths were mentioned by only one director, although several of these strengths can be 
grouped together:  
• usefulness of the recommendations, which included attributes like focusing on end users, 
ensuring usability, responding to the concerns of donors, and filling a gap; 
• evidence-based process, which included attributes like obtaining evidence in a rigorous 
way, drawing on good data, basing recommendations on research, using cost-effectiveness 
analyses, testing the recommendations, and conducting validation studies; 
• experience-based process, which included attributes like involving people with practical 
experience and, while this was also considered a weakness, developing “instinct-based” 
recommendations; 
• expert-based process, which included attributes like working with knowledgeable experts 
and obtaining consensus among experts; 
• systematic approach, which included attributes like using a standardised method and 
adopting “guideline logic” rather than “technocratic” approach; 
• group members without conflicts of interest; 
• good group process as a key element of the meeting structure; and 
• up-to-date recommendations. 
 
While most directors identified one or more ways in which the recommendation-
development process could have been improved, four did not identify any way in which 
improvements could have been made. Directors singled out the use of evidence more 
commonly than any other area for improvement. Comments included: 
• “I would have liked to have had more evidence to base recommendations on. We should 
have conducted a literature search.” 
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• “We never had the evidence base well documented. We should have reviewed evidence at 
a very early stage.” 
• “The lack of resources does limit the ability to develop evidence-based 
recommendations.” 
• “[Director General] Brundtland came in and said “evidence, evidence, evidence” but the 
approach to expert committees hasn’t changed since the 1950s – many see WHO as a 
technical agency and therefore we should have a comprehensive review of 
recommendation processes, including expert committees.” 
• “Maybe what WHO needs is more work on the guidelines for guidelines.” 
 
Directors also frequently singled out the timeliness of the recommendations as an area for 
improvement. Directors offered comments like “It could have happened earlier” and “It could 
have been done faster… perhaps better with one person being responsible for keeping up the 
momentum.” Recommendations were sometimes prepared as a “technical consultation” 
document as a way of reducing both the amount of time needed to produce recommendations 
and the level of expectations about the rigour of the process used. One director described a 
recommendation-containing report that was: 
 
“… prepared as a technical consultation document so it has a lower status. They should 
have been prepared by a study group and, even better, an expert committee. People have 
asked how can you say a technical consultation document is a WHO recommendation, but 
it has stood the test of time with other initiatives coming to similar conclusions. You can’t 
develop a guideline in less than a year, but this doesn’t work when there’s pressure. 
Should there be a guideline for urgent recommendations?” 
 
WHO use of evidence  15   
Several directors identified the match between the resources available and the resources 
needed to develop recommendations and attention to dissemination and implementation 
strategies as other areas for improvement. Two directors identified a lack of resources as the 
problem. For example, one said: “We had inadequate time and resources. The 
recommendation was developed during about ten months. I believe this is too short a time. 
Would like to be able to use a more systematic approach.” Two other directors indicated that 
the resources required to develop recommendations was the problem. For example, one said: 
“It was a cumbersome and resource-demanding exercise.” Several directors observed that 
recommendations were not being implemented after they were published. One said: “We 
published it, but just left it there . . . The recommendations were never transformed into a 
programmatic approach. It is a common in-house failure to transform recommendations into 
action.” Another said: “The marketing of it, making people aware, should have been thought 
of earlier.”  
 
Directors highlighted a number of other weaknesses with the processes used to develop 
recommendations, however, most were mentioned by only one director. The weaknesses 
included a failure to involve key organizations, a failure to use evidence from other sectors, 
the creation of high expectations, a conflict over data, failure to use the guidelines for WHO 
guidelines (which were published after the process was started), the perceived need to choose 
between having a “mega-meeting” or using a smaller group to develop recommendations, the 
failure to involve patients sufficiently, the failure to fit recommendations to health systems, 
not having had consultations earlier in the process, and not collecting baseline data for an 
evaluation. 
 
What is expected and used and with what effect?  
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The anticipated benefits, potential harms and costs of adherence to the recommendations 
were unevenly considered. All directors could cite one or more anticipated benefits of 
adherence, such as simplification of treatment, improved quality of care, better management 
of technologies, and reduced morbidity and mortality. Many fewer directors could cite one or 
more potential harms of adherence. Indeed, a number of directors reported that there were no 
potential harms in adhering to their departments’ recommendations. For example, one director 
argued: “No harms are likely, since the recommendations were made by the top experts.” 
Those directors who could cite potential harms provided relatively general examples, such as 
side effects and the consequences of misapplication or adaptation of the recommendations. 
One director reported that the potential harms were only considered implicitly in the 
discussion because it was feared that emphasizing the risks might reduce the value of the 
recommendations, which were intended to help countries advocate for disease control 
programs. Many directors identified both direct costs and opportunity costs associated with 
adhering to the recommendations. 
 
When asked about how their department’s recommendations have been used, directors 
provided examples like educators using them in training programs, WHO staff using them in 
their work in countries, and member states using them in developing policies. Several 
directors reported requests for reports, webpage hits, or translations of reports as indicators of 
the usefulness of the recommendations. Only a few directors reported any systematic 
monitoring of the uptake of their recommendations. Similarly, only a few reported completed 
or planned evaluations. This may be due, in part, to a lack of resources, as suggested by one 
director: “We would love to do it through a rigorous process. The problem is that that this 
would require resources that we do not currently have and cannot reasonably expect in the 
foreseeable future.” Another reported “no plans for evaluation because the cycle of scientific 
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developments is so quick that it isn’t feasible.” Most of the reported evaluations were not 
rigorous evaluations of their effectiveness. They included the collection of indicators, case 
studies, site visits, and feedback at meetings. 
 
How were four clinical guidelines developed? 
The four clinical guidelines that we examined did not emphasize evidence about 
effectiveness or processes that would allow for the explicit incorporation of other types of 
information.24-27 Two of the reports were called “guidelines”, one a “technical consultation”, 
and another a description of “the technical basis for the guidelines”. Two of the reports stated 
that “This document is not a formal publication of WHO” on the page containing the 
publication information. Three of the reports (including the supporting documentation) did 
not contain a methods section. The fourth report contained a brief (less than one page) 
methods section. In all four reports the recommendations were neither itemized nor explicitly 
linked to evidence. All reports included references to primary studies or secondary sources. 
Three of the reports cited at least one systematic review as a reference (and at most four). The 
descriptions of the recommendation-development processes used in developing the 
recommendations were brief and provided little information about group processes (Box 1).  
 
What if any progress is being made?  
A number of directors indicated that there was a growing recognition of the need for more 
systematic and transparent approaches to developing recommendations and that there was 
progress in this direction. One director observed: “There has been a culture change, but there 
is room for improvement.” Another director said: “It is improving, but slowly. Many 
departments are doing OK, while others are not doing so well. Some have been too close to 
industry, often because of lack of resources.” A third director also provided a long-range 
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view: “We are in the middle of a process, which needs time. There is increasing 
understanding of the need for evidence-based guidance and it is becoming part of the WHO 
culture.” 
 
Discussion 
The guidelines for WHO guidelines do not appear to be closely followed when WHO 
develops recommendations for member states. For example, systematic reviews and concise 
summaries of findings (e.g., balance sheets) are rarely used, which means that evidence is 
generally not retrieved, appraised, synthesized and interpreted using systematic and 
transparent methods. Processes for developing recommendations typically rely heavily on 
experts in a particular content area and not on representatives of those who will have to live 
with the recommendations or on experts in particular methodological areas (e.g., information 
retrieval, systematic reviews, economic evaluations, and group facilitation). While many of 
the people we spoke with viewed this as a problem, many others did not. Relatively little 
attention appears to have been given by WHO to how to best help member states adapt global 
recommendations or take account of local needs, conditions, resources, costs and values. 
Relatively little attention has also been given by WHO to roles and responsibilities related to 
effective dissemination and implementation strategies and their rigorous evaluation. 
 
The strengths of our study include achieving a high response rate among the directors of a 
broad cross-section of WHO departments, conducting interviews that probed the contexts for 
and processes used in developing specific guidelines or policies, augmenting the interviews 
with document reviews in a domain that could be expected to be a best-case scenario 
(developing clinical practice guidelines as opposed to public health or policy 
recommendations), and undertaking two efforts to verify our interpretations (sharing our 
WHO use of evidence  19   
written summaries of each interview with directors and sharing our findings at a variety of 
forums within WHO). The verification process yielded only minor corrections. The study’s 
weaknesses include the potential for social desirability bias, particularly in terms of 
identifying the use of evidence as an area for improvement. 
 
While the guidelines for WHO guidelines are consistent with guidelines developed by 
other organizations,28 the actual processes used to develop recommendations at WHO appear 
to be less rigorous than at other organizations. None of the directors reported using the 
guidelines for WHO guidelines and only two reported plans to use them. Few directors 
reported using processes that were consistent with the guidelines. An unpublished in-house 
review of WHO guidelines, which was undertaken just prior to our study using the AGREE 
instrument,14 found that the vast majority of WHO guidelines did not meet most of the 
AGREE criteria (Personal communication, Robin Gray, 8 September 2003). Reviews of 
clinical practice guidelines produced by other organizations have also found that guidelines 
often do not adhere to guidelines for guidelines.29-31 WHO also is not alone in its failure to 
recognise the danger of inadequately evaluated public health and policy interventions which, 
like clinical interventions, can also have unintended consequences.32 However, many 
organizations now report using systematic and transparent methods to develop clinical, public 
health and policy recommendations, including a growing number of organizations funded by 
government. 33-35 
 
Progress in how WHO develops and disseminates recommendations for member states 
and in how it supports member states in their efforts to adapt and implement 
recommendations will require leadership. WHO’s Cabinet recognised the need for using 
systematic and transparent methods to develop recommendations when it endorsed the 
WHO use of evidence  20   
guidelines for WHO guidelines in 2003.23 Yet no mechanisms have been put in place to 
support and monitor adherence to the guidelines and our study suggests that the guidelines are 
not being followed. A number of directors reported a shift towards a culture that supports 
using systematic and transparent methods in developing recommendations but this shift 
appeared to pertain more to clinical than policy recommendations. WHO has not clearly 
articulated whether and how it will support member states in their efforts to adapt and 
implement recommendations. 
 
Progress will also require the resources necessary for WHO to undertake 
recommendation-development processes in a transparent and defensible way and close 
attention to the current and emerging research literature related to these processes. All of the 
directors we interviewed were highly motivated and trying hard to do a good job. Many were 
frustrated by a lack of resources and feelings of being pressured by a lack of time and 
perceptions of urgency. WHO relies heavily on external financial support, so it could be 
argued that resources will have to be found outside the organization. However, WHO could 
do much better with the resources it has, both by setting priorities for guidelines and by 
adhering to its own guidelines for WHO guidelines. Given that these guidelines may be most 
germane to the development of clinical practice guidelines and public health 
recommendations, future iterations of the guidelines will need to incorporate the emerging 
research literature about developing policy recommendations.12 
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Box 1: Recommendation-development processes used in four guidelines 
 
The following descriptions are taken from the four guidelines included in our document 
review. 
 
1. “. . . year-long process of international consultative meetings in 2001, in which more than 
200 clinicians, scientists, government representatives, representatives of civil society and 
people living with . . . from more than 60 countries participated.” 
 
“The recommendations included in this publication reflect the best current practices based 
on a review of existing evidence. When the body of evidence was not conclusive, expert 
consensus was used as a basis for recommendations.”  
 
2. “This document was prepared for the WHO . . . by . . . The document was reviewed by the 
WHO Regional Advisors . . . and approved by the WHO Strategy and Technical Advisory 
Group . . .”  
 
3. “A WHO Technical Consultation on . . . was held in Geneva, Switzerland on 4 and 5 April 
2001. Participants reflected a wide range of expertise in the document and use of . . . 
drugs. 
 
“The technical consultation took the form of presentations based on working papers and 
plenary discussions, on the basis of which specific conclusions and recommendations 
were agreed. The proceedings of the meeting and working papers form the basis of this 
report.” 
 
4. “The guidelines . . . are based on both expert clinical opinion and research results. A 
technical review of existing programme guidelines was carried out with the cooperation of 
12 WHO technical programmes through the WHO Working Group on . . . Some 
modifications were required . . . The draft guidelines were subsequently reviewed in 
several versions by clinicians and experts in specific diseases who had experience in 
clinical and public health work in developing countries, then examined in research studies 
and by field-testing the training course.” 
 
“Sufficient data were not available to make several guideline decisions…. Six studies 
were carried out . . .” 
 
“The case management charts and the modules were revised based on this experience and 
on the results of additional studies and analyses to help identify the best clinical indicators 
. . .” 
 
“The revised materials were made available to countries for closely monitored use . . .” 
